Prot #KN035SAR201: ENVASARC: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy

Project: Research project

Project Details

StatusActive
Effective start/end date4/20/214/20/24

Funding

  • TRACON Pharmaceuticals, Inc. (Prot #KN035SAR201)